Search

Search Results

• UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)

  José Luis Piñana, Estela Giménez, Lourdes Vázquez, María Ángeles Marcos, Manuel Guerreiro, Rafael Duarte, Ariadna Pérez, Carlos de Miguel, Ildefonso Espigado, Marta González-Vicent, María Suarez-Lledó, Irene García-Cadenas, Rodrigo Martino, Angel Cedillo, Monserrat Rovira, Rafael de la Cámara, David Navarro, Carlos Solano

  e2024065

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.065

  3706

  Suppl. Files: 1026

  PDF: 1015

  Html: 101

• CMV IN HEMATOPOIETIC STEM CELL TRANSPLANTATION

  Rafael de la Camara

  e2016031

  2016-06-20

  https://doi.org/10.4084/mjhid.2016.031

  4684

  PDF: 1702

  HTML: 2685

  Untitled: 188

• IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES

  Silvia Maria Trisolini, Alessandro Laganà, Saveria Capria

  e2024060

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.060

  1914

  PDF: 1696

  HTML: 115

• PREVENTION AND TREATMENT OF HEPATITIS VIRUS INFECTION IN HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS

  Suparno Chakrabarti, Somnath Mukherjee

  e2009017

  2009-12-10

  https://doi.org/10.4084/mjhid.2009.017

  738

  PDF: 536

  HTML: 2438

• LETERMOVIR PRIMARY CYTOMEGALOVIRUS PROPHYLAXIS IN ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT RECIPIENTS: COULD INFECTION AND DISEASE NO LONGER BE A SIGNIFICANT PROBLEM? Letermovir and Cytomegalovirus Prophylaxis in HSCT

  Fabian Herrera

  e2024039

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.039

  1231

  PDF: 975

  HTML: 105

• IMPACT OF PRETRANSPLANT DONOR AND RECIPIENT CYTOMEGALOVIRUS SEROSTATUS ON OUTCOME FOR MULTIPLE MYELOMA PATIENTS UNDERGOING REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANSPLANTATION.

  Jean Elcheikh

  e2013026

  2013-04-10

  https://doi.org/10.4084/mjhid.2013.026

  1229

  PDF: 707

  HTML: 1381

• In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

  Jochen J Frietsch, Detlef Michel, Thomas Stamminger, Friederike Hunstig, Sebastian Birndt, Ulf Schnetzke, Sebastian Scholl, Andreas Hochhaus, Inken Hilgendorf

  e2019001

  2019-01-01

  https://doi.org/10.4084/mjhid.2019.001

  2226

  PDF: 1375

  HTML: 229

• EPSTEIN-BARR VIRUS RELATED LYMPHOPROLIFERATIONS AFTER STEM CELL TRANSPLANTATION

  Simona Sica, Elisabetta Metafuni, Silvia Bellesi, Patrizia Chiusolo

  e2009019

  2009-12-14

  https://doi.org/10.4084/mjhid.2009.019

  1232

  PDF: 542

  HTML: 2963

• Evaluation of Hepatitis B and C Reactivation in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors

  Nathalia Sena de Oliveira Silva, Gislaine Duarte, Samuel de Souza Medina, Guilherme Brasil Duffles Amarante, Carmino Antonio de Souza, Katia Borgia Barbosa Pagnano

  e2026001

  2026-01-01

  https://doi.org/10.4084/MJHID.2026.001

  566

  PDF: 345

  Html: 66

• COMPARISON OF INFECTIOUS COMPLICATIONS IN PATIENTS RECEIVING HIGH-DOSE CYCLOPHOSPHAMIDE AS GVHD AFTER TRANSPLANTATION FROM A 9/10 HLA-MATCHED UNRELATED DONOR WITH STANDARD GVHD PROPHYLAXIS AFTER TRANSPLANT FROM A FULL MATCHING DONOR Infection With PTCy Versus Standard GvHD Prophylaxis

  Selim SAYIN

  e2024016

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.016

  1298

  PDF: 1264

  HTML: 77